PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Morphological analysis of the biopsies for prostate cancer (PCa) often is a difficult task due to heterogeneity and multifocality of tumors. At the same time, a lot of data exist about the potential molecular genetic markers of PCa. The aim of our study is to determine of PCA3 and TMPRSS2:ERG genes expression in benign hyperplasia (BPH), low and high grade intraepithelial neoplasia (PIN), PCa for revealing of diagnostic value of those genes expression in benign and precancerous changes in prostate. Total RNA was isolated from 53 biopsies, reverse transcription was performed, gene expression was determined by real time PCR (RT-PCR) then deltaCt index was determined as Ct(PCA3) - Ct(KLK3). Average deltaCt and its SD in BPH were 8,28±3,13, low PIN - 8,56±2,64, high PIN -8,98±1,69, PCa - 1,08±2,36. We have demonstarted that deltaCt did not differ in patients with BPH, low and high grade PIN, whereas significantly increased in PCa relative to any of the three groups listed above (p<0.0001). Expression of TMPRSS2:ERG was absent in BPH, PIN, but it was detected in 40% (4/10) of PCa cases. ROC-analysis showed that the AUC (area under ROC-curve with 95% CI, p<0.0001) was 0,98 ± 0,02 in the analysis of a combination of overexpression of PCA3 and TMPRSS2:ERG. Thus, the expression analysis of the PCA3 and chimeric oncogene TMPRSS2:ERG in biopsy cannot be used for differential diagnosis of BPH, low and high grade PIN. However, overexpression of PCA3 and expression of TMPRSS2:ERG are characteristic in PCa. Expression analysis of these genes by the proposed RT-PCR modification at the threshold level deltaCt 3,22 has diagnostic accuracy 90% to detect PCa in biopsy specimens.

Texto integral

Acesso é fechado

Sobre autores

D. Mikhaylenko

N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation

PhD Russia, Moscow

D. Perepechin

N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation; Research Centre for Medical Genetics

Russia, Moscow

M. Grigoryeva

N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation

Russia, Moscow

T. Zhinzhilo

N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation

Russia, Moscow

N. Safronova

N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation

Russia, Moscow

G. Efremov

N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation

Russia, Moscow

A. Sivkov

N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation

Russia, Moscow

Bibliografia

  1. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 250 с.
  2. Пальцев М.А., Залетаев Д.В. Системы генетических и эпигенетических маркеров в диагностике онкологических заболеваний. М.: Медицина, 2009. 153-187.
  3. Clarke R.A., Zhao Z., Guo A.Y., Roper K., Teng L., Fang Z.M., Samaratunga H., Lavin M.F., Gardiner RA. New genomic structure for prostate cancer specific gene 3 (PCA3) within BMMC1: implication for prostate cancer detection and progression. PLoS ONE. 2009;4(3):e4995.
  4. Ефремов Г.Д., Сивков А.В., Михайленко Д.С., Григорьева М.В. Комбинация маркеров РСА3 и TMPRSS2-ERG в ранней диагностике рака предстательной железы (обзор литературы). Экспериментальная и клиническая урология. 2014;3:20-26.
  5. Killick E., Bancroft E., Kote-Jarai Z., Eeles R. Beyond prostate-specific antigen future biomarkers for the early detection and management of prostate cancer. Clin. Oncol. 2012;24:545-555.
  6. Kirby R., Fitzpatrick J.M. Optimising repeat prostate biopsy decisions and procedures. BJU Int. 2012;109(12):1750-1754.
  7. Chevli K.K., Duff M., Walter P., Yu C., Capuder B., Elshafei A., Malczewski S., Kattan M. W., Jones J.S. Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy. J. Urol. 2014;191(6): 1743-1748.
  8. Capoluongo E., Zambon C.F., Basso D., Boccia S., Rocchetti S., Leoncini E., Palumbo S., Padoan A., Albino G., Todaro A., Prayer-Galetti T., Zattoni F., Zuppi C., Plebani M. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals. Clin. Chim. Acta. 2014;429:46-50.
  9. Pepe P., Fraggetta F., Galia A., Skonieczny G., Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cutoff: 20 or 35? Int. Braz. J. Urol. 2012;38(4):489-495.
  10. De Luca S., Passera R., Milillo A., Coda R., Randone D.F. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score. BJU Int. 2012;110(11 Pt B):E778-E782.
  11. De Luca S., Passera R., Cappia S., Bollito E., Randone D.F., Milillo A., Papotti M., Porpiglia F. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies. BJU Int. 2014;114:E56-E61.
  12. Klatte T., Waldert M., de Martino M., Schatzl G., Mannhalter C., Remzi M. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J. Urol. 2012;30:405-410.
  13. Chan S.W., Nguyen P.N., Violette P., Brimo F., Taguchi Y., Aprikian A., Chen J.Z. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers. Cancer Med. 2013;2(1):63-75.
  14. Young A., Palanisamy N., Siddiqui J., Wood D.P., Wei J.T., Chinnaiyan A.M., Kunju L.P., Tomlins S.A. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am. J. Clin. Pathol. 2012;138(5):685-696.
  15. Robert G., Jannink S., Smit F., Aalders T., Hessels D., Cremers R., Mulders P.F., Schalken J.A. Rational basis for the combination of PCA3 and the TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate. 2013;73(2): 113-120.
  16. Park K., Dalton J.T., Narayanan R., Barbieri C.E., Hancock M.L., Bostwick D.G., Steiner M.S., Rubin M.A. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 2014; 32(3):206-211.
  17. Leyten G.H., Hessels D., Jannink S.A., Smit F.P., de Jong H., Cornel E.B., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C., van Oort I.M., Mulders P.F., Hulsbergen-van de Kaa C.A., Schalken J.A. Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers of prostate cancer. Eur Urol. 2014;65(3):534-542.
  18. Goode R.R., Marshall S.J., Duff M., Chevli E., Chevli K.K. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate. 2013;73(1):48-53.
  19. Hansen J., Auprich M., Ahyai S.A. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur. Urol. 2013;63(2):201-209.
  20. De Luca S., Passera R., Bollito E., Manfredi M., Scarpa R.M., Sottile A., Randone D.F., Porpiglia F. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy. Anticancer Res. 2014;34:7159-7166.
  21. Merola R., Tomao L., Antenucci A., Sperduti I., Sentinelli S., Masi S., Mandoj C., Orlandi G., Papalia R., Guaglianone S., Costantini M., Cusumano G., Cigliana G., Ascenzi P., Gallucci M., Conti L. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J. Exp. Clin. Cancer Res. 2015;34:15.
  22. Luo Y., Gou X., Huang P., Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J. Androl. 2014;16:487-492.
  23. Wang Y., Liu X.J., Yao X.D. Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score. Chin. J. Cancer Res. 2014;26(4):493-500.
  24. Ng C.F., Yeung R., Chiu P., Lam N.Y., Chow J., Chan B. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med. J. 2012;18:459-465.
  25. Foj L., Mila M., Mengual L., Luque P., Alcaraz A., Jiménez W., Filella X. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta. 2014;435:53-58.
  26. Chan S.W., Nguyen P.N., Violette P., Brimo F., Taguchi Y., Aprikian A., Chen J.Z. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers. Cancer Medicine. 2013;2(1):63-75.
  27. Yao Y.H., Wang H., Li B.G., Tang Y. Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and metaanalysis. Tumor Biol. 2014;35(3):2157-2166.
  28. Taris M., Irani J., Blanchet P., Multigner L., Cathelineau X., Fromont G. ERG expression in prostate cancer: the prognostic paradox. Prostate. 2014;74:1481-1487.
  29. Eguchi F.C., Faria E.F., Neto C.S., Longatto-Filho A., Zanardo-Oliveira C., Taboga S.R., Campos S.G. The role of TMPRSS2 :ERG in molecular stratification of Pca and its association with tumor aggressiveness: a study in Brazilian patients. Sci Rep. 2014;35:9597-9602.
  30. Velarti S., Dimitriadis E., Kontogianni-Katsarou K., Savvani A., Sdrolia E., Pantazi G., Stefanakis S., Trangas T., Pandis N., Petraki K. Detection of TMPRSS2:ERG fusion gene in benign prostatic hyperplasia. Tumor Biol. 2014;35:9597-9602.
  31. Burdova A., Bouchal J., Tavandzis S., Kolar Z. TMPRSS2-ERG gene fusion in prostate cancer. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2014;158(4):502-510.
  32. Udager A.M., Shi Y., Tomlins S.A., Alva A., Siddiqui J., Cao X., Pienta K.J., Jiang H., Chinnaiyan A.M., Mehra R. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate. 2014;74(12):1199-1208.
  33. Tandefelt D.G., Boormans J., Hermans K., Trapman J. ETS fusion genes in prostate cancer. Endocrine-Related Cancer. 2014;21: R143-R152.
  34. Park K., Dalton J.T., Narayanan R., Barbieri C.E., Hancock M.L., Bostwick D.G., Steiner M.S., Rubin M.A. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 2013; 32:206-211.
  35. Altintas D.M., Allioli N., Decaussin M., de Bernard S., Ruffion A., Samarut J., Vlaeminck-Guillem V. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS ONE. 2013;8(6):e66278.
  36. Hansen J., Auprich M., Ahyai S.A. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur. Urol. 2013;63(2):201-209.
  37. Perdona S., Bruzzese D., Ferro M., Autorino R., Marino A., Mazzarella C., Perruolo G., Longo M., Spinelli R., Di Lorenzo G., Oliva A., De Sio M., Damiano R., Altieri V., Terracciano D. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate. 2013;73(3):227-235.
  38. Sartori D.A., Chan D.W. Biomarkers in prostate cancer: what’s new? Curr. Opin. Oncol. 2014;26(3):259-264.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2015

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies